Bharat Biotech’s CRDMO Nucelion Partners and VeGen Bio are collaborating to develop and manufacture a CAR-T cell therapy in India. Coverage across outlets describes the partnership as covering multiple stages of development and production, including technology transfer and clinical and commercial manufacturing support.
The Hindu says Nucelion will act as the technology transfer and manufacturing partner for VeGen Bio’s lead candidate, VL-2511, for multiple myeloma. Business Line highlights broader manufacturing goals such as process optimisation to improve production economics and expand patient access. Times of India frames the work around developing what it describes as India’s first dual-target CAR-T cell therapy, focusing on the therapy’s target design.
Overall, all three reports agree the collaboration involves Nucelion and VeGen Bio working together on CAR-T cell therapy in India, with technology transfer and clinical and commercial manufacturing included, though emphasis differs between therapy specificity and manufacturing and access impacts.
